Skip to main content
OpenTrials
Completed

NCT Number: NCT00801827

PET Imaging and Bariatric Surgery

The purpose of this study is to look at certain areas of the brain that are related to addictive behaviors, such as overeating. These areas are called 'dopamine type 2 receptors' (DRD2/3) and other studies have shown that obese people have less of these. We propose that low DRD2/3 availability seen in morbidly obese subjects will change with weight loss associated with bariatric surgery.

Completed

Looking for future studies?

Notify Me

Key information

Conditions

Obesity, Morbid Behavior Behavior, Addictive Body Weight Compulsive Behavior Impulsive Behavior Nutrition Disorders Nutritional and Metabolic Diseases Obesity Overnutrition Overweight Pathological Conditions, Signs and Symptoms Signs and Symptoms

Age range

18 year–60 year

Sex eligibility

All sexes

Study type

Interventional

Phase

Phase 1

Primary location

Vanderbilt University Medical Center

Nashville, Tennessee, 37232, United States

About this study

The purpose of this study is to look at certain areas of the brain that are related to addictive behaviors, such as overeating. These areas are called 'dopamine type 2 receptors' (DRD2/3) and other studies have shown that obese people have less of these. We propose that low DRD2/3 availability seen in morbidly obese subjects will change with weight loss associated with bariatric surgery.

Who can participate

Healthy volunteers accepted: No

Only the study team can determine whether someone qualifies for participation.

Inclusion criteria

  • Ages 18-60 years
  • BMI equal to or greater than 40, or equal to or greater than 35 if there are 2 or more co-morbidities
  • Weight less than 350 pounds

Exclusion criteria

  • History of substance abuse,including but not limited to alcohol, cocaine, marijuana, heroin, nicotine
  • History of psychiatric disorders
  • Use of any antidepressants or psychotropics in the past 12 months
  • Diabetes Mellitis
  • Positive pregnancy test
  • Any condition felt by the PI or co-investigators to interfere with the individual's ability to complete the study
  • Subjects on medications for the last 3 months, such as sibutramine, which could affect the quality of the study, as determined by the PI
  • Inability to travel to Nashville, TN four times

Treatment and study plan

F-18 (fallypride)

Drug

Subjects undergoing bariatric surgery will have Positron Emission Tomography (PET)scans of their brains using the radioligand fallypride before and after the operation.

Primary outcomes

  1. Regional DRD2/3 Binding Percent Changes After Bariatric Surgery

    Time frame: ~7 weeks

Sponsors and collaborators

Lead sponsor

Vanderbilt University Medical Center

Other

Registry information

Important dates

Study start
2007
Primary completion
2011
Study completion
2012
First posted
Dec 4, 2008
Registry last updated
Mar 17, 2017

OpenTrials presents study information sourced from ClinicalTrials.gov. The official registry record should be consulted for the latest information.

View the official ClinicalTrials.gov record (opens in a new tab)

This listing is for discovery and informational purposes only. It is not medical advice, does not guarantee that a study is recruiting, and does not determine eligibility. Contact the study team and a qualified healthcare professional when considering participation.

Related clinical trials

Published trials that share one or more normalized conditions with this study.